What is claimed:

1. A compound represented by the Formula I:



I

wherein:

R^1 is a moiety represented by the formula



where

Z is selected from the group consisting of CH and NH, and Q is a moiety such that R^1 is a substituted or unsubstituted monocyclic or bicyclic heteroaryl which has at least two carbon atoms in the heteroaryl ring system;

X is selected from the group consisting of CH_2, O, S, and NH;

Y is selected from the group consisting of CH_2, O, and S, provided that at least one of X and Y is CH_2, or X and Y together with the bond there-between form a cyclopropyl;

R^2 and R^3 are independently selected from the group consisting of hydrogen, methyl, halogen, trifluoromethyl, and cyano; and

R^4 is selected from the group consisting of

 and  ,

where R^5 is selected from the group consisting of substituted and unsubstituted aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O-R^7, NR^8R^9, C_1-C_8 alkyl, and monocyclic heterocycloalkyl, R^6 is selected from the group consisting of substituted and unsubstituted aryl, heteroaryl, cycloalkyl, heterocycloalkyl, alkenyl, O-R^7, $C(O)R^7$, NR^8R^9, C_2-C_8 alkyl, and monocyclic heterocycloalkyl, where R^7 is selected from the group consisting of substituted and unsubstituted alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, R^8 is selected from the group consisting of hydrogen, and substituted and unsubstituted alkyl,

and R^9 is selected from the group consisting of substituted and unsubstituted alkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl;

or a pharmaceutically acceptable prodrug, pharmaceutically active metabolite, or pharmaceutically acceptable salt thereof.

2. A compound according to claim 1, wherein R^1 is a substituted or unsubstituted heteroaryl group selected from the group consisting of:



and

;

X is selected from the group consisting of CH_2, O, and S;

Y is selected from the group consisting of CH_2 and S, provided that at least one of X and Y is CH_2;

R^2 and R^3 are independently selected from the group consisting of hydrogen, methyl, fluorine, and chlorine, and

R^4 is selected from the group consisting of



where R^5 is selected from the group consisting of substituted and unsubstituted aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O-R^7, NR^8R^9, C_1-C_8 alkyl, and monocyclic

heterocycloalkyl, R^6 is selected from the group consisting of substituted and unsubstituted aryl, heteroaryl, cycloalkyl, heterocycloalkyl, alkenyl, O-R^7, C(O)R^7, NR^8R^9, C_2-C_8 alkyl, and monocyclic heterocycloalkyl, where R^7 is selected from the group consisting of substituted and unsubstituted alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, R^8 is selected from the group consisting of hydrogen and substituted and unsubstituted alkyl, and R^9 is selected from the group consisting of substituted and unsubstituted alkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl;

or a pharmaceutically acceptable prodrug, pharmaceutically active metabolite, or pharmaceutically acceptable salt thereof.

3. A compound represented by the Formula II:



II

wherein:

X is selected from the group consisting of CH_2, O, and S;

Y is is selected from the group consisting of CH_2 and S, provided that at least one of X and Y is CH_2;

R^2 and R^3 are independently selected from the group consisting of hydrogen, methyl, fluorine, and chlorine;

R^4 is selected from the group consisting of



and



,

where R^5 and R^6 are each independently selected from the group consisting of substituted and unsubstituted aryl and heteroaryl; and R^{10} is selected from the group consisting of substituted and unsubstituted alkenyl, aryl, heteroaryl, and HNR^9, where R^9 is selected from the group consisting of substituted and unsubstituted alkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl;

or a pharmaceutically acceptable prodrug, pharmaceutically active metabolite, or pharmaceutically acceptable salt thereof.

4. A compound according to claim 3, wherein R^5 and R^6 are each independently selected from the group consisting of substituted and unsubstituted aryl; or a pharmaceutically acceptable salt, a pharmaceutically acceptable prodrug, or a pharmaceutically active metabolite thereof, or a pharmaceutically acceptable salt of said metabolite.

5. A compound according to claim 3, wherein R^5 and R^6 are each independently selected from the group consisting of substituted and unsubstituted heteroaryl; or a pharmaceutically acceptable salt, a pharmaceutically acceptable prodrug, or a pharmaceutically active metabolite thereof, or a pharmaceutically acceptable salt of said metabolite.

6. A compound represented by the Formula III:



III

wherein:

X is selected from the group consisting of CH_2, O, S, and NH;

Y is selected from the group consisting of CH_2, O, and S, provided that at least one of X and Y is CH_2, or X and Y together with the bond there-between form a cyclopropyl;

R^2 and R^3 are independently selected from the group consisting of hydrogen, methyl, halogen, trifluoromethyl, and cyano; and

R^4 is selected from the group consisting of



where R^5 is selected from the group consisting of substituted and unsubstituted aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O-R^7, NR^8R^9, C_1-C_8 alkyl, and monocyclic heterocycloalkyl, R^6 is selected from the group consisting of substituted and unsubstituted

aryl, heteroaryl, cycloalkyl, heterocycloalkyl, alkenyl, O-R^7, C(O)R^7, NR^8R^9, C_2-C_8 alkyl, and monocyclic heterocycloalkyl, where R^7 is selected from the group consisting of substituted and unsubstituted alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, R^8 is selected from the group consisting of hydrogen and substituted and unsubstituted alkyl, and R^9 is selected from the group consisting of substituted and unsubstituted alkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl;

or a pharmaceutically acceptable prodrug, pharmaceutically active metabolite, or pharmaceutically acceptable salt thereof.

7. A compound according to claim 6, wherein:

X is selected from the group consisting of CH_2, O, and S;

Y is selected from the group consisting of CH_2 and S, provided that at least one of X and Y is CH_2;

R^2 and R^3 are independently selected from the group consisting of hydrogen, methyl, fluorine, and chlorine; and

R^4 is selected from the group consisting of



and



,

where R^5 and R^6 are each independently selected from the group consisting of substituted and unsubstituted aryl and heteroaryl;

or a pharmaceutically acceptable salt, a pharmaceutically acceptable prodrug, or a pharmaceutically active metabolite thereof, or a pharmaceutically acceptable salt of said metabolite.

8. A compound according to claim 7, wherein R^5 and R^6 are each independently selected from the group consisting of substituted and unsubstituted aryl; or a pharmaceutically acceptable salt, a pharmaceutically acceptable prodrug, or a pharmaceutically active metabolite thereof, or a pharmaceutically acceptable salt of said metabolite.

9. A compound according to claim 7, wherein R^5 and R^6 are each independently selected from the group consisting of substituted and unsubstituted heteroaryl; or a pharmaceutically acceptable salt, a pharmaceutically acceptable prodrug,

or a pharmaceutically active metabolite thereof, or a pharmaceutically acceptable salt of said metabolite.

10. A compound according to claim 7, wherein:

X is CH_2;

Y is S;

R^2 and R^3 are independently selected from the group consisting of hydrogen, methyl, fluorine, and chlorine; and

R^4 is selected from the group consisting of



where R^5 and R^6 are each independently selected from the group consisting of substituted and unsubstituted aryl and heteroaryl;

or a pharmaceutically acceptable salt, a pharmaceutically acceptable prodrug, or a pharmaceutically active metabolite thereof, or a pharmaceutically acceptable salt of said metabolite.

11. A compound according to claim 10, wherein R^5 and R^6 are each independently selected from the group consisting of substituted and unsubstituted aryl; or a pharmaceutically acceptable salt, a pharmaceutically acceptable prodrug, or a pharmaceutically active metabolite thereof, or a pharmaceutically acceptable salt of said metabolite.

12. A compound selected from the group consisting of

N-(3,4,5-Trimethoxyphenyl)-3-[(pyrazin-2-yl)sulfanylmethyl]benzamide;

N-(3,4,5-Trimethoxyphenyl)-3-[(5-amino-2H-[1,2,4]triazol-3-yl)sulfanylmethyl] benzamide;

N-(4-Isopropyl-3-methylphenyl)-3-[(pyrazin-2-yl)sulfanylmethyl]benzamide;

N-(4-Isopropyl-3-methylphenyl)-3-[(5-amino-2H-[1,2,4]triazol-3-yl)sulfanylmethyl]benzamide;

N-(4-Isopropyl-3-methylphenyl)-3-[(1H-pyrazolo[3,4-d]pyrimidin-4-yl)sulfanylmethyl]benzamide;

N-(2-Methylquinolin-6-yl)-3-[(pyrazin-2-yl)sulfanylmethyl]benzamide;

N-(3-Isopropylphenyl)-3-[(pyrazin-2-yl)sulfanylmethyl]benzamide;

N-(3,5-Dibromo-4-methylphenyl)-3-[(pyrazin-2-yl)sulfanylmethyl]benzamide;

N-(3,4,5-Trimethoxyphenyl)-3-[(1H-pyrazolo[3,4-d]pyrimidin-4-yl)sulfanylmethyl] benzamide;

N-(3,4,5-Trimethoxyphenyl)-3-[(1H-pyrazolo[3,4-d]pyrimidin-4-yl)sulfanylmethyl] benzamide;

N-(Quinolin-6-yl)-3-[(1H-pyrazolo[3,4-d]pyrimidin-4-yl)sulfanyl-methyl]benzamide;

N-(5-Methylisoxazol-3-yl)-3-[(1H-pyrazolo[3,4-d]pyrimidin-4-yl)sulfanylmethyl] benzamide;

N-(Pyridin-4-yl)methyl-3-[(1H-pyrazolo[3,4-d]pyrimidin-4-yl)sulfanylmethyl] benzamide;

N-(1,3-Benzodioxyl-5-ylmethyl)-3-[(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-sulfanylmethyl] benzamide;

N-(2-Methoxybenzyl)-3-[(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-sulfanylmethyl]benzamide;

N-(2-Phenylethyl)-3-[(1H-pyrazolo[3,4-d]pyrimidin-4-yl)sulfanyl-methyl]benzamide;

N-(2-Methoxyphenyl)-3-[(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-sulfanylmethyl]benzamide;

N-[3-(N-Methyl-N-phenylamino)propyl]-3-[(5-methyl-1H-1,2,4-triazol-3-yl) sulfanylmethyl]benzamide;

N-(1,3-Benzodioxyl-5-ylmethyl)-3-[(5-methyl-1H-1,2,4-triazol-3-yl)sulfanylmethyl] benzamide;

N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(1H-pyrazolo[3,4-d]-pyrimidin-4-yl-sulfanyl) methyl]benzamide;

N-(3,3-Diphenylpropyl)-3-{[(5-methyl-1H-1,2,4-triazol-3-yl)-sulfanyl]methyl}benzamide;

3-{[(5-Methyl-1H-1,2,4-triazol-3-yl)-sulfonyl]methyl}-N-phenethylbenzamide;

3-[(1H-Pyrazolo[3,4-d]pyrimidin-4-yl)sulfanylmethyl]-N(3-isopropylphenyl)-benzamide;

3-[(1H-Pyrazolo[3,4-d]pyrimidin-4-yl)sulfanylmethyl]-N(3-trifluoromethyl-5-methoxyphenyl)-benzamide;

3-[(1H-Pyrazolo[3,4-d]pyrimidin-4-yl)sulfanylmethyl]-N(3,5-bis-trifluoromethylphenyl)-benzamide;

3-[(1H-Pyrazolo[3,4-d]pyrimidin-4-yl)sulfanylmethyl]-N(3-t-butylphenyl)-benzamide;

3-[(1H-Pyrazolo[3,4-d]pyrimidin-4-yl)sulfanylmethyl]-N(4-isopropylphenyl)-benzamide;

3-[(1H-Pyrazolo[3,4-d]pyrimidin-4-yl)sulfanylmethyl]-N(4-trifluoromethoxyphenyl)-benzamide;

3-[(1H-Pyrazolo[3,4-d]pyrimidin-4-yl)sulfanylmethyl]-N(3,5-dimethylphenyl)-benzamide;

3-[(1H-Pyrazolo[3,4-d]pyrimidin-4-yl)sulfanylmethyl]-N(3-(2-hydroxyethyl)phenyl)-benzamide;

3-[(1H-Pyrazolo[3,4-d]pyrimidin-4-yl)sulfanylmethyl]-N(4-dimethylaminophenyl)-benzamide;

3-[(1H-Pyrazolo[3,4-d]pyrimidin-4-yl)sulfanylmethyl]-N(3-trifluoromethylsulfonyl phenyl)-benzamide;

3-[(1H-Pyrazolo[3,4-d]pyrimidin-4-yl)sulfanylmethyl]-N(3-dimethylaminophenyl)-benzamide;

3-[(5-Cyanoamino-2H-[1,2,4]triazol-3-yl)sulfanylmethyl]-N-(3,4,5-trimethoxyphenyl) benzamide;

3-[(5-(Methoxycarbonylamino)-2H-[1,2,4]triazol-3-yl)sulfanylmethyl]-N-(3,4,5-trimethoxyphenyl)benzamide;

N-(3,4,5-Trimethoxyphenyl)-3-[(5-acetylamino-2H-[1,2,4]triazol-3-yl)sulfanylmethyl] benzamide;

N-(4-Isopropyl-3-methylphenyl)-3-[(pyrazin-2-yl)methylsulfanyl]benzamide;

N-(2-Methylquinolin-6-yl)-3-[(pyrazin-2-yl)methylsulfanyl]benzamide;

N-(2-Methyl-quinolin-6-yl)-3-(pyridin-3-ylmethylsulfanyl)-benzamide dihydrochloride;

N-(2-methyl-quinolin-6-yl)-3-[{5-(phenylamino)-2-H-pyrazol-3-yl}methylsulfanyl] benzamide;

N-(3,4,5-trimethoxyphenyl)-3-[2-(5-phenylamino-2H-pyrazol-3-yl)ethyl]benzamide;

3-[{5-((E)-2-(4-Hydroxy-3-methoxyphenyl)ethenyl)-2H-pyrazol-3-yl}-methylsulfanyl]-N-(2-methylquinolin-6-yl)benzamide;

3-[5-(2-(3,4-Dimethoxyphenyl)ethenyl)-2H-pyrazol-3-yl)methylsulfanyl]-N-(2-methylquinolin-6-yl)benzamide;

3-(2-{5-[(E)-2-(3,4-Dimethoxyphenyl)ethenyl]-2H-pyrazol-3-yl}-ethyl)-N-(3-methyl-4-isopropylphenyl)-benzamide;

4-Fluoro-3-[{5-((E)-1-propenyl)-2H-pyrazol-3-yl}methoxy]-N-[4-(pyrrolidin-1-yl)-3-trifluoromethylphenyl]benzamide;

3-(2-{5-[(E)-2-(3,4-Dimethoxyphenyl)ethenyl]-2H-pyrazol-3-yl}-ethyl)-N-(3-methyl-4-isopropylphenyl)-benzamide;

N-(4-Isopropyl-3-methyl-phenyl)-3-{2-[5-(4-(methylsulfamoyl)-phenylamino)-2H-pyrazol-3-yl]-ethyl}-benzamide;

N-(2-Methylquinolin-6-yl)-3-[2-(5-phenylamino-2H-pyrazol-3-yl)ethyl]benzamide;

N-(4-isopropyl-3-methylphenyl)-3-[2-(5-phenylamino-2H-pyrazol-3-yl)ethyl]benzamide;

N-(4-Isopropyl-3-methyl-phenyl)-3-{2-[5-(6-methoxypyridin-3-yl)amino-2H-pyrazol-3-yl]-ethyl}-benzamide;

N-(4-Dimethylamino-3-trifluoromethylphenyl)-3-{2-[5-(6-methoxypyridin-3-yl)amino-2H-pyrazol-3-yl]ethyl}-benzamide;

N-(6-Dimethylamino-5-trifluoromethylpyridin-3-yl)-3-{2-[5-(6-methoxypyridin-3-yl)amino-2H-pyrazol-3-yl]ethyl}-benzamide;

N-(3,5-Dichloro-4-dimethylaminophenyl)-3-{2-[5-(6-methoxy-pyridin-3-yl)amino-2H-pyrazol-3-yl]ethyl}benzamide;

3-{2-[5-(6-Methoxypyridin-3-yl)amino-2H-pyrazol-3-yl]-ethyl}-N-(4-pyrrolidin-1-yl-3-trifluoromethylphenyl)benzamide;

3-{2-[5-(6-Methoxypyridin-3-yl)amino-2H-pyrazol-3-yl]-ethyl}-N-[4-(4-*t*-butoxycarbonylpiperazin-1-yl)-3-trifluoromethylphenyl]benzamide;

3-{2-[5-(6-Methoxypyridin-3-yl)amino)-2H-pyrazol-3-yl]ethyl}-N-(4-piperazin-1-yl-3-trifluoromethylphenyl)benzamide;

4-Fluoro-3-[{5-(pyridin-3-yl)amino-2H-pyrazol-3-yl}methoxy]-N-[((4-pyrrolidin-1-yl)-3-trifluoromethylphenyl)benzamide;

N-(4-Isopropyl-3-methyl-phenyl)-3-[2-(5-phenylamino-2-H-pyrazol-3-yl)-cyclopropyl]-benzamide;

3-[({3-[(E)-2-(4-hydroxy-3-methoxyphenyl)ethenyl]-1H-pyrazol-5-yl}methyl)amino]-N-(3-methyl-4-isopropylphenyl)benzamide;

3-[({5-[(E)-2-(4-hydroxy-3-methoxyphenyl)ethenyl]-1H-pyrazol-3-yl}methyl)amino]-N-phenyl)benzamide;

4-Fluoro-N-[4-(imidazol-1-yl)-3-trifluoromethylphenyl]-3-[5-(6-methoxypyridin-3-yl)amino-2H-pyrazol-3-ylmethoxy]-benzamide;

4-Fluoro-3-[5-(6-methoxy-pyridin-3-yl)amino-2H-pyrazol-3-yl]methoxy-N-(4-pyrrolidin-1-yl-3-trifluoromethyl-phenyl)-benzamide;

4-Fluoro-3-[5-(6-methoxypyridin-3-yl)amino-2H-pyrazol-3-yl]methoxy-N-(3-methoxy-5-trifluoromethyl-phenyl)-benzamide;

N-(4-Isopropyl-3-methyl-phenyl)-3-(Isoquinolin-4-yl)methoxy-benzamide;

3-(Isoquinolin-4-yl)methoxy-N-(3,4,5-trimethoxyphenyl)benzamide hydrochloride;

3-(Isoquinolin-4-yl)methoxy-N-(2-methyl-quinolin-6-yl)-benzamide hydrochloride;

3-(Isoquinolin-4-yl)methoxy-N-(2-methyl-4-methylsulfanyl-quinolin-6-yl)-benzamide hydrochloride;

3-(Pyridin-3-yl)methoxy-N-(3,4,5-trimethoxyphenyl)benzamide;

N-(Naphthalen-2-yl)-3-(pyridin-3-yl)methoxybenzamide;

N-(1-Allyl-1H-indol-5-yl)-3-(pyridin-3-yl)methoxy-benzamide;

3-(Pyridin-3-yl)methoxy-N-quinolin-6-yl-benzamide;

N-(2-Methyl-quinolin-6-yl)-3-(pyridin-3-yl)methoxy-benzamide;

N-(4-Isopropyl-3-methyl-phenyl)-4-fluoro-3-(Isoquinolin-4-yl)methoxy-benzamide;

N-(4-Isopropyl-3-methyl-phenyl)-4-methyl-3-(Isoquinolin-4-yl)methoxy-benzamide;

N-(4-Isopropyl-3-methyl-phenyl)-4-chloro-3-(Isoquinolin-4-yl)methoxy-benzamide;

3-(6-Aminopyridin-3-yl)methoxy-N-(4-Isopropyl-3-methyl-phenyl)benzamide;

3-(6-Aminopyridin-3-yl)methoxy-N-(2-methyl-quinolin-6-yl)-benzamide;

3-(6-Acetylaminopyridin-3-yl)methoxy-N-(2-methyl-quinolin-6-yl)-benzamide;

3-(6-Acetylaminopyridin-3-yl)methoxy-N-(4-isopropyl-3-methyl-phenyl)-benzamide;

4-Fluoro-N-(1,2,3,4-tetrahydroquinolin-6-yl)-3-(isoquinolin-4-yl-methoxy)-benzamide bistrifluoroacetic acid salt;

N-(2,2-difluorobenzo[1,3]dioxol-4-yl-ethyl)-benzamide trifluoroacetic acid salt;

4-Fluoro-N-(2-methyl-1,2,3,4-tetrahydroquinolin-6-yl)-3-(isoquinolin-4-yl-methoxy)-benzamide bistrifluoroacetic acid salt;

N'-{4-[3-(4-Isopropyl-3-methyl-phenylcarbamoyl)-phenoxy;

N-(4-Isopropyl-3-methyl-phenyl)-3-{1-[N'-(3-methoxy-benzylidene)-hydrazino]-isoquinolin-4-ylmethoxy}-benzamide;

N-(3,5-Diallyl-4-methyl-phenyl)-3-(isoquinolin-4-ylmethoxy)-benzamide;

N-(3,5-Dibromo-4-methyl-phenyl)-3-(isoquinolin-4-ylmethoxy)-benzamide;

3-(Isoquinolin-4-ylmethoxy)-N-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-benzamide;

3-(Isoquinolin-4-ylmethoxy)-N-(3-trifluoromethoxy-phenyl)-benzamide;

N-(2,4-Dimethylquinolin-6-yl)-3-(isoquinolin-4-ylmethoxy)-benzamide;

3-(Isoquinolin-4-ylmethoxy)-benzoic acid N'-(4-trifluoromethyl-phenyl)-hydrazide;

N-Benzyloxy-3-(isoquinolin-4-ylmethoxy)-benzamide;

3-(Isoquinolin-4-ylmethoxy)-benzoic acid N'-phenyl-hydrazide;

N-(5,7-dimethyl[1,8]naphthydrin-2-yl)-3-(isoquinolin-4-ylmethoxy)-benzamide;

3-(Isoquinolin-4-ylmethoxy)-N-(1,1,3,3-tetramethyl-1,3-dihydroisobenzofuran-5-yl)-benzamide;

N-(3,5-Dichloro-4-pyrrolidin-1-yl-phenyl)-4-fluoro-3-(pyridin-3-ylmethoxy)-benzamide;

4-Fluoro-N-(4-morpholin-4-yl-3-trifluoromethyl-phenyl)-3-(pyridin-3-ylmethoxy)-benzamide;

4-Fluoro-N-[4-(piperazin-1-yl)-3-trifluoromethylphenyl]-3-(pyridin-3-yl)methoxybenzamide;

4-Fluoro-N-(4-morpholin-4-yl-3-trifluoromethyl-phenyl)-3-(isoquinolin-4-ylmethoxy)-benzamide;

4-Fluoro-N-(4-piperazin-1-yl-3-trifluoromethyl-phenyl)-3-(isoquinolin-4-ylmethoxy)-benzamide;

4-Fluoro-*N*-(4-morpholin-4-yl-3-trifluoromethyl-phenyl)-3-(quinolin-3-ylmethoxy)-benzamide;

4-Fluoro-N-(4-piperazin-1-yl-3-trifluoromethyl-phenyl)-3-(quinolin-3-ylmethoxy)-benzamide;

N-(3,5-Dichloro-4-morpholin-4-yl-phenyl)-4-fluoro-3-(pyridin-3-ylmethoxy)-benzamide;

N-(3,5-Dichloro-4-piperazin-1-yl-phenyl)-4-fluoro-3-(pyridin-3-ylmethoxy)-benzamide;

4-Fluoro-N-[4-(piperazin-1-yl)-3-trifluoromethylphenyl]-3-(pyridin-3-yl)methoxybenzamide;

4-Fluoro-N-(4-(imidazol-1-yl-3-trifluoromethylphenyl]-3-(pyridin-3-yl)methoxybenzamide;

4-Fluoro-N-(4-pyrazol-1-yl-3-trifluoromethyl-phenyl)-3-(pyridin-3-ylmethoxy)-benzamide;

4-Fluoro-3-(pyridin-3-ylmethoxy)-N-(4-[1,2,4]triazol-1-yl-3-trifluoromethyl-phenyl)-benzamide;

N-(3,5-Dichloro-4-imidazol-1-yl-phenyl)-4-fluoro-3-(pyridin-3-ylmethoxy)-benzamide;

3-(5-Bromo-pyridin-3-ylmethoxy)-4-fluoro-N-(4-piperazin-1-yl-3-trifluoromethyl-phenyl)-benzamide;

3-(2-Isoquinolin-4-yl-ethyl)-N-phenyl-benzamide;

3-(2-Isoquinolin-4-yl-ethyl)-N-(3,3,5-trimethyl-cyclohexyl)-benzamide;

N-(4-Isopropyl-3-methyl-phenyl)-3-(2-isoquinolin-4-yl-ethyl)-benzamide;

3-(2-Isoquinolin-4-yl-ethyl)-N-(2-methyl-quinolin-6-yl)-benzamide;

N-(3,5-Dibromo-4-methyl-phenyl)-3-(2-isoquinolin-4-yl-ethyl)-benzamide;

N-(4,6-Dimethyl-pyridin-2-yl)-3-(2-isoquinolin-4-yl-ethyl)-benzamide;

2-Chloro-4-fluoro-N-(4-isopropyl-3-methyl-phenyl)-5-(2-isoquinolin-4-yl-ethyl)-benzamide;

2,4-Difluoro-N-(4-isopropyl-3-methyl-phenyl)-5-(2-isoquinolin-4-yl-ethyl)-benzamide;

2-Fluoro-N-(4-isopropyl-3-methyl-phenyl)-5-(2-isoquinolin-4-yl-ethyl)-benzamide;

N-(2-Methyl-quinolin-6-yl)-3-(2-pyridin-3-yl-ethyl)-benzamide hydrochloride;

N-(4-Isopropyl-3-methyl-phenyl)-3-(2-pyridin-3-yl-ethyl)-benzamide;

N-{3-[(1H-pyrazolo[3,4-d]-pyrimidin-4-ylsulfanylmethyl]phenyl}-(3-bromo-4-methyl) benzamide;

N-{3-[(1H-pyrazolo[3,4-d]-pyrimidin-4-ylsulfanylmethyl]phenyl}-3,5-bis(trifluoromethyl) benzamide;

N-{3-[(1H-pyrazolo[3,4-d]-pyrimidin-4-yl)sulfanylmethyl]phenyl}-(4-hydroxy-3-methoxy) benzamide;

N-{3-[(1H-pyrazolo[3,4-d]-pyrimidin-4-yl)sulfanylmethyl]phenyl}-(4-hydroxy-3-t-butyl) benzamide;

N-{3-[(1H-pyrazolo[3,4-d]-pyrimidin-4-yl)sulfanylmethyl]phenyl}-4-t-butylbenzamide;

N-{3-[(1H-pyrazolo[3,4-d]-pyrimidin-4-yl)sulfanylmethyl]phenyl}-(4-phenoxy)benzamide;

N-{3-[(1H-pyrazolo[3,4-d]pyrimidin-4-ylsulfanyl)methyl]phenyl}-N'-[3,5-bis-(trifluoromethyl)phenyl]urea;

N-{3-[(1H-pyrazolo[3,4-d]pyrimidin-4-ylsulfanyl)methyl]phenyl}-N'-(pyridin-3-yl)urea;

N-{3-[(1H-pyrazolo[3,4-d]-pyrimidin-4-yl)sulfanylmethyl]phenyl}-(3,5-di-t-butyl) benzamide;

3-Bromo-4-hydroxy-N-{3-[(1H-pyrazolo[3,4-d]-pyrimidin-4-yl)sulfanylmethyl]phenyl}-benzamide;

N-{3-[(1H-pyrazolo[3,4-d]-pyrimidin-4-yl)sulfanylmethyl]phenyl}-quinoline-6-carboxamide;

5-Fluoro-N-{3-[(1H-pyrazolo[3,4-d]-pyrimidin-4-yl)sulfanylmethyl]phenyl}-indole-2-carboxamide;

N-{3-[(1H-pyrazolo[3,4-d]-pyrimidin-4-yl)sulfanylmethyl]phenyl}-indole-6-carboxamide;

(R/S)-2-(2-methylphenyl)-N-{3-[(1H-pyrazolo[3,4-d]pyrimidin-4-ylsulfanyl)methyl)-methyl} phenyl}butanamide;

3-*t*-Butyl-4-hydroxy-N-{3-[5-(6-methoxy-pyridin-3-ylamino)-2 H-pyrazol-3-ylmethyl sulfanyl]-phenyl}-benzamide;

3-*t*-Butyl-4-hydroxy-N-[3-(pyridin-3-ylmethylsulfanyl)-phenyl}-benzamide;

3-*t*-Butyl-4-hydroxy-N-[3-(isoquinolin-4-ylmethylsulfanyl)-phenyl}-benzamide;

N-[3-(5-Bromo-pyridin-3-ylmethoxy)-phenyl]-3-t-butyl-4-hydroxy-benzamide;

4-Acetoxy-3-t-butyl-N-[3-(pyridin-3-ylmethoxy)phenyl]-benzamide;

4-Acetoxy-3-t-butyl-N-[3-(isoquinolin-4-ylmethoxy)phenyl]-benzamide;

3-t-Butyl-4-hydroxy-N-[3-(pyridin-3-ylmethoxy)-phenyl]-benzamide;

3-t-Butyl-4-hydroxy-N-[3-(isoquinolin-4-ylmethoxy)-phenyl]-benzamide;

1-[3-(pyridin-3-ylmethoxy)phenylcarbamoyl]pyrrolidine;

4-[3-(pyridin-3-ylmethoxy)phenylcarbamoyl]morpholine;

3-[{6-Methoxy-7-(2-methoxyethoxy)cinnolin-4-yl}sulfanylmethyl]-*N*-phenyl-benzamide;

3-[2-(6-Acetylamino-pyridin-3-yl)-ethyl]-N-(4-piperazin-1-yl-3-trifluoro-methylphenyl)-benzamide dihydrochloride;

3-[2-(6-Amino-pyridin-3-yl)-ethyl]-N-(4-piperazin-1-yl-3-trifluoromethyl-phenyl)-benzamide dihydrochloride;

3-[2-(3H-Imidazo[4,5-b]pyridin-6-yl)-ethyl]-N-(4-piperazin-1-yl-3-trifluoromethyl-phenyl)-benzamide dihydrochloride;

5-{2-[3-(Piperazin-1-yl-trifluoromethyl-phenylcarbamoyl)-phenyl]-ethyl}-nicotinamide dihydrochloride;

5-{2-[3-(Piperazin-1-yl-trifluoromethyl-phenylcarbamoyl)-phenyl]-ethyl}-nicotinic acid methyl ester dihydrochloride;

4-Fluoro-3-[2-(3H-imidazo[4,5-b]pyridin-6-yl)-ethyl]-N-(4-piperazin-1-yl-3-trifluoromethyl-phenyl)-benzamide dihydrochloride; and

4-Fluoro-3-(5-furan-2-yl-pyridin-3-ylmethoxy)-N-(4-piperazin-1-yl-3-trifluoromethyl-phenyl)-benzamide dihydrochloride;

or a pharmaceutically acceptable salt, pharmaceutically acceptable prodrug, or pharmaceutically active metabolite thereof or a pharmaceutically acceptable salt of said metabolite.

13. A compound selected from the group consisting of the compounds corresponding to Example B-27 (Compounds 1-244), Example V-6d (Compounds 1-176), Example V-7b (Compounds 1-43) and Example V-14 (Compounds 1-88), or a pharmaceutically acceptable salt, pharmaceutically acceptable prodrug, or pharmaceutically active metabolite thereof or a pharmaceutically acceptable salt of said metabolite.

14. A pharmaceutically acceptable salt of a pharmaceutically active metabolite of a compound according to claim 1.

15. A pharmaceutical composition for modulating or inhibiting the activity of a protein kinase receptor comprising:

(a) a therapeutically effective amount of an agent selected from the group consisting of a compound according to claim 1, a pharmaceutically acceptable prodrug thereof, a pharmaceutically active metabolite thereof, and a pharmaceutically acceptable salt thereof; and

(b) a pharmaceutically acceptable carrier, diluent, or vehicle therefor.

16. A pharmaceutical composition for modulating or inhibiting the activity of a protein kinase receptor comprising:

(a) a therapeutically effective amount of a pharmaceutically acceptable salt of a pharmaceutically active metabolite of a compound according to claim 1;

(b) a pharmaceutically acceptable carrier, diluent, or vehicle therefor.

17. A method of treating a mammalian disease condition mediated by protein kinase activity, comprising administering to a mammal in need thereof a therapeutically effective amount of an agent selected from the group consisting of a compound according to claim 1, a pharmaceutically acceptable prodrug thereof, a pharmaceutically active metabolite thereof, and a pharmaceutically acceptable salt thereof.

18. A method according to claim 17, wherein the mammalian disease condition is associated with tumor growth, cell proliferation, or angiogenesis.

19. A method of modulating or inhibiting the activity of a protein kinase receptor, comprising contacting the kinase receptor with an effective amount of an agent selected from the group consisting of a compound according to claim 1, a pharmaceutically acceptable prodrug thereof, a pharmaceutically active metabolite thereof, and a pharmaceutically acceptable salt thereof.

20. A method according to claim 19, wherein the protein kinase receptor is a VEGF receptor.